<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02685709</url>
  </required_header>
  <id_info>
    <org_study_id>OOC-ACM-302</org_study_id>
    <secondary_id>2015-002854-11</secondary_id>
    <nct_id>NCT02685709</nct_id>
  </id_info>
  <brief_title>Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly</brief_title>
  <acronym>MPOWERED</acronym>
  <official_title>A Phase 3, Randomized, Active Controlled Study to Evaluate Maintenance of Response, Safety and Patient Reported Outcomes in Acromegaly Patients Treated With Octreotide Capsules vs. Parenteral Somatostatin Receptor Ligands</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiasma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiasma, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Octreotide capsule is a novel, orally-administered formulation of the commercially-available
      injectable drug octreotide. In a recent phase 3 trial, oral octreotide capsules demonstrated
      sustained biochemical response up to 13 months in patients with acromegaly previously managed
      with somatostatin analog injections (ref).

      The purpose of this study is to compare the efficacy safety and patient reported outcomes
      between oral octreotide capsules and injectable somatostatin analogs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a phase 3, randomized, open-label, active controlled, multicenter study to
      evaluate maintenance of response, safety and patient reported outcomes (PROs) in acromegaly
      patients treated with octreotide capsules and in patients treated with SOC parenteral SRLs,
      who previously tolerated and demonstrated biochemical control on both treatments.

      The core study will consist of three phases: a Screening phase, Run-in phase and a Randomized
      Controlled Treatment Phase (RCT).

      Eligible patients who are biochemically controlled on parenteral SRLs will be switched to
      octreotide capsules for a 26-week Run-in phase. During this phase the effective dose for each
      patient will be determined through dose titration.

      Patients whose acromegaly is been controlled biochemically on octreotide capsules at the end
      of the Run-in Phase will enter a 36-week open-label Randomized Controlled Treatment Phase,
      where they will be randomized to continue on octreotide capsules or switch back to their
      injectable SRL treatment (as received prior to Screening).

      Following the completion of the core study (Screening, Run-in and RCT phases), eligible
      patients will be offered to enter the Study Extension phase and receive octreotide capsules
      until product marketing or study termination.

      A Sub-study, in selected sites, would allow patients with in-adequate biochemical control on
      octreotide capsules during the Run-in Phase to enter a Combination phase and receive
      co-administration of octreotide capsules with cabergoline tablets for a total of 36 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IGF-1 Time Weighted Average (TWA), during the RCT phase</measure>
    <time_frame>62 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in acromegaly symptoms</measure>
    <time_frame>62 weeks</time_frame>
    <description>Acromegaly Index of Severity Score (AIS) - Headache, Swelling of extremities, Joint pain, Sweating and Fatigue, assessed by severity (0-3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with clinical and biochemical response</measure>
    <time_frame>62 weeks</time_frame>
    <description>Biochemical response - IGF-1 TWA Clinical response - maintained or improved acromegaly symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcomes</measure>
    <time_frame>62 weeks</time_frame>
    <description>Acro-TSQ - newly developed and validated patient reported outcome questionnaire</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Acromegaly</condition>
  <arm_group>
    <arm_group_label>Run-in phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral octreotide capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RCT phase - Oral</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral octreotide capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RCT phase - Injectables</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Injectable somatostatin analogs (octreotide or lanreotide)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination phase (sub-study)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Octreotide capsules plus cabergoline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Octreotide capsules</intervention_name>
    <description>Octreotide capsules 40mg/day, 60mg/day, 80mg/day</description>
    <arm_group_label>Run-in phase</arm_group_label>
    <arm_group_label>RCT phase - Oral</arm_group_label>
    <arm_group_label>Combination phase (sub-study)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Injectable Somatostatin Analogs (octreotide or lanreotide)</intervention_name>
    <description>Octreotide - 10, 20, 30mg. Lanreotide 60,90, 120mg.</description>
    <arm_group_label>RCT phase - Injectables</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabergoline</intervention_name>
    <description>Cabergoline - 3.5mg/week</description>
    <arm_group_label>Combination phase (sub-study)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of acromegaly

          -  Treatment with Somatostatin analogs injections (octreotide or lanreotide) for at least
             6 months

          -  Biochemical control (IGF -1 &lt; 1.3 x ULN and GH &lt; 2.5ng/mL)

        Exclusion Criteria:

          -  Injections of long-acting somatostatin analogs, at a dosing interval &gt; 8 weeks.

          -  Pituitary radiotherapy within 5 years

          -  Pituitary surgery within six months

          -  Patients who previously participated in CH-ACM-01 study

          -  Any clinically significant uncontrolled concomitant disease

          -  Symptomatic cholelithiasis

          -  Previous treatment with:

          -  Pegvisomant, within 12 weeks

          -  Dopamine agonists, within 6 weeks

          -  Pasireotide, within 12 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Fleseriu, M.D., FACE</last_name>
    <role>Study Chair</role>
    <affiliation>Northwest Pituitary Center, Oregon Health &amp; Science University , Portland, OR, USA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Engage Health</last_name>
    <phone>+1-855-676-9733</phone>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Keck Medical Center of University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>John H. Stroger, Jr. Hospital of Cook County</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Palm Research Center, Inc.</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Rutgers - Robert Wood Johnson Medical School</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Allegheny Endocrinology Associates</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Midstate Endocrinology Associates</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Research Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Innere Medizin Klinische Abteilung für Endokrinologie und Diabetologie</name>
      <address>
        <city>Graz</city>
        <zip>A-8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Obermayer-Pietsch, MD</last_name>
      <phone>0114331638512383</phone>
      <email>barbara.obermayer@medunigraz.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Wien</name>
      <address>
        <city>Wien</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anton Luger, MD, PhD</last_name>
      <phone>+ 43 14 040043100</phone>
      <email>anton.luger@meduniwien.ac.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerald Raverot, MD, PhD</last_name>
      <phone>+ 33 4 72 11 93 25</phone>
      <email>gerald.raverot@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Bicêtre APHP</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phillipe Chanson, MD, PhD</last_name>
      <phone>+ 33 1 45 21 37 08</phone>
      <email>Philippe.chanson@bct.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Praxis für Endokrinologie und Diabetologie Dr M Droste</name>
      <address>
        <city>Oldenburg</city>
        <zip>26122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Magyar Honvedseg Egeszsegugyi Kozpont</name>
      <address>
        <city>Budapest</city>
        <zip>H-1062</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pecs</name>
      <address>
        <city>Pecs</city>
        <zip>H-7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szegedi Tudományegyetem, I. Belgyógyászati Klinika</name>
      <address>
        <city>Szeged</city>
        <zip>H-6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Policlinico di Monserrato U.O.C. Endocrinologia e Diabetologia</name>
      <address>
        <city>Monserrato</city>
        <zip>09042</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Università di Pisa Dipartimento di Medicina Clinica e Sperimentale</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario A. Gemelli Università Cattolica del S.Cuore S.C. Endocrinologia e Malattie del Metabolismo</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital of LUHS Kauno Klinikos</name>
      <address>
        <city>Kaunas</city>
        <zip>LT-50009</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robertas Knispelis, MD</last_name>
      <phone>+370 6 869 9352</phone>
      <email>robertas.knispelis@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vaidotas Urbanavicius Individuali Imonė</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-10207</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vaidotas Urbanavicius, MD, PhD</last_name>
      <phone>+370 5 236 5189</phone>
    </contact>
    <contact_backup>
      <email>vaidotas.urbanavicius@santa.lt</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Katedra i Klinika Endokrynologii i Chorob Wewnetrznych Gdanski Uniwersytet Medyczny</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-211</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny nr 1 we Wroclawiu, Klinika Endokrynologii, Diabetologii i Leczenia Izotopami</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-367</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>&quot;C.I. Parhon&quot; National Institute of Endocrinology I Clinical Endocrinology Department - Endemic goitier and its complications</name>
      <address>
        <city>Bucharest</city>
        <zip>011863</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Antrium Multidisciplinary Medical Clinic</name>
      <address>
        <city>Barnaul</city>
        <zip>656043</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nina Leonova, MD, PhD</last_name>
      <email>endo-akkb@mail.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Interregional Clinical Diagnostic Center</name>
      <address>
        <city>Kazan</city>
        <zip>420101</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Isaeva, MD, PhD</last_name>
      <email>isaeva.com@mail.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regional State Budgetary Healthcare Institution Regional State Hospital</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof. Sergey Dogadin, DMSc</last_name>
      <email>sadogadin@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sechenov Moscow First State Medical University</name>
      <address>
        <city>Moscow</city>
        <zip>119881</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Pavlova, PhD</last_name>
      <phone>+7 916 678 66 79</phone>
      <email>mgp.med@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>&quot;Atlas&quot; Medical Center</name>
      <address>
        <city>Moscow</city>
        <zip>121170</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yury Poteshkin, MD, PhD</last_name>
      <phone>(7495) 212-0888</phone>
      <email>yuriy.poteshkin@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vladimirsky Moscow Regional Research Clinical Institute</name>
      <address>
        <city>Moscow</city>
        <zip>129110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Dreval, PhD</last_name>
      <phone>+7 495 681 1308</phone>
      <email>dreval@diabet.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Novosibirsk State Regional Clinical Hospital</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof. Irina Bondar, DMSc</last_name>
      <email>bondaria@oblmed.nsk.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Institution &quot;V. A. Almazov Federal North-West Medical Research Centre&quot; of the Ministry of Health of the Russian Federation</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>194156</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Grineva, MD, PhD</last_name>
      <email>grineva_e@mail.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>&quot;Centre Diabetes&quot; LLC</name>
      <address>
        <city>Samara</city>
        <zip>443041</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrey Verbovoy, DMDc, Prof.</last_name>
      <phone>+7 8462 734 243</phone>
      <email>andreyy.verbovoyy@rambler.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Centre of Serbia, Clinic for Endocrinology Diabetes and Metabolic Diseases</name>
      <address>
        <city>Belgrade</city>
        <zip>11 000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Djuro Macut, MD, PhD</last_name>
      <email>djmacut@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de la Ribera</name>
      <address>
        <city>Alzira</city>
        <zip>46600</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Fajardo, MD, PhD</last_name>
      <phone>+34 96 245 85 80</phone>
      <email>CfajardoO@hospital-ribera.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Barcelona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Puig-Domingo, MD, PhD</last_name>
      <phone>+34 93 497 88 60</phone>
      <email>mpuigd@igtp.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rogelio Garcia Centeno, MD</last_name>
      <email>roges82@msn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Santiago de Compostela</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felipe Casanueva Freijo, MD</last_name>
      <email>felipe.casanueva@usc.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Campus Del Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>46013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Maria Venegas Moreno, MD</last_name>
      <email>evam.venegas.sspa@juntadeandalucia.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2GW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Central Manchester University Hospitals NHS Foundation Trust, Manchester Royal Infirmary</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Infirmary</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Hallamshire Hospital</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Lithuania</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.chiasmapharma.com</url>
    <description>Click here for more information about Chiasma</description>
  </link>
  <reference>
    <citation>Melmed S, Popovic V, Bidlingmaier M, Mercado M, van der Lely AJ, Biermasz N, Bolanowski M, Coculescu M, Schopohl J, Racz K, Glaser B, Goth M, Greenman Y, Trainer P, Mezosi E, Shimon I, Giustina A, Korbonits M, Bronstein MD, Kleinberg D, Teichman S, Gliko-Kabir I, Mamluk R, Haviv A, Strasburger C. Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial. J Clin Endocrinol Metab. 2015 Apr;100(4):1699-708. doi: 10.1210/jc.2014-4113. Epub 2015 Feb 9. Erratum in: J Clin Endocrinol Metab. 2016 Oct;101(10 ):3863.</citation>
    <PMID>25664604</PMID>
  </reference>
  <reference>
    <citation>Melmed S. New therapeutic agents for acromegaly. Nat Rev Endocrinol. 2016 Feb;12(2):90-8. doi: 10.1038/nrendo.2015.196. Epub 2015 Nov 27. Review.</citation>
    <PMID>26610414</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2016</study_first_submitted>
  <study_first_submitted_qc>February 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2016</study_first_posted>
  <last_update_submitted>December 4, 2017</last_update_submitted>
  <last_update_submitted_qc>December 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Octreotide Capsules</keyword>
  <keyword>Acromegaly</keyword>
  <keyword>Somatostatin</keyword>
  <keyword>Mpowered</keyword>
  <keyword>OOC-ACM-302</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acromegaly</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Octreotide</mesh_term>
    <mesh_term>Lanreotide</mesh_term>
    <mesh_term>Angiopeptin</mesh_term>
    <mesh_term>Cabergoline</mesh_term>
    <mesh_term>Somatostatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

